Matthew Trendowski

The promise of sonodynamic therapy.

The real deal: using cytochalasin B in sonodynamic therapy to preferentially damage leukemia cells.

The rhetoric of cancer.

Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach.

Using cytochalasins to improve current chemotherapeutic approaches.

Tolerated doses in zebrafish of cytochalasins and jasplakinolide for comparison with tolerated doses in mice in the evaluation of pre-clinical activity of microfilament-directed agents in tumor model systems in vivo.

Enlargement and multinucleation of u937 leukemia and MCF7 breast carcinoma cells by antineoplastic agents to enhance sensitivity to low frequency ultrasound and to DNA-directed anticancer agents.

Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration.

Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models.

The inherent metastasis of leukaemia and its exploitation by sonodynamic therapy.

Preferential enlargement of leukemia cells using cytoskeletal-directed agents and cell cycle growth control parameters to induce sensitivity to low frequency ultrasound.

Effects of alkylation and immunopotentiation against Ehrlich ascites murine carcinoma in vivo using novel tetra-O-acetate haloacetamido carbohydrate analogs.

Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy.

PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction.